MANCHESTER, N.H.--(BUSINESS WIRE)--Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, today announced that it has submitted an Abbreviated New Drug Application (ANDA) for chewable metformin with the U.S. Food and Drug Administration (FDA). The Reference Listed Drug at the FDA is Bristol-Myers Squibb’s Glucophage® product ([metformin hydrochloride] Tablets).
